164 related articles for article (PubMed ID: 35816286)
21. Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.
Abida W; Hahn AW; Shore N; Agarwal N; Sieber P; Smith MR; Dorff T; Monk P; Rettig M; Patel R; Page A; Duff M; Xu R; Wang J; Barkund S; Pankov A; Wang A; Junttila MR; Multani PS; Daemen A; Chow Maneval E; Logothetis CJ; Morris MJ
Clin Cancer Res; 2024 Mar; 30(6):1111-1120. PubMed ID: 38226958
[TBL] [Abstract][Full Text] [Related]
22. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ
Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
[TBL] [Abstract][Full Text] [Related]
23. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Macaulay VM; Lord S; Hussain S; Maroto JP; Jones RH; Climent MÁ; Cook N; Lin CC; Wang SS; Bianchini D; Bailey M; Schlieker L; Bogenrieder T; de Bono J
Br J Cancer; 2023 Oct; 129(6):965-973. PubMed ID: 37537253
[TBL] [Abstract][Full Text] [Related]
24. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment.
Madan RA; Schmidt KT; Karzai F; Peer CJ; Cordes LM; Chau CH; Steinberg SM; Owens H; Eisner J; Moore WR; Dahut WL; Gulley JL; Figg WD
Clin Genitourin Cancer; 2020 Aug; 18(4):258-267.e1. PubMed ID: 32327394
[TBL] [Abstract][Full Text] [Related]
26. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
[TBL] [Abstract][Full Text] [Related]
27. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
[TBL] [Abstract][Full Text] [Related]
28. Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer.
Freedland SJ; Li S; Pilon D; Bhak RH; Narkhede S; Lefebvre P; Young-Xu Y
Curr Med Res Opin; 2021 Apr; 37(4):635-642. PubMed ID: 33571020
[TBL] [Abstract][Full Text] [Related]
29. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A;
Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
[TBL] [Abstract][Full Text] [Related]
30. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study.
Soleimani M; Zou K; Sunderland K; Struss W; Eigl BJ; Nappi L; Kollmannsberger CK; Finch D; Noonan K; Vergidis J; Zulfiqar M; Chi KN; Khalaf DJ
Eur J Cancer; 2021 Jul; 152():215-222. PubMed ID: 34130153
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
33. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer.
Graff JN; Liang LW; Kim J; Stenzl A
Future Oncol; 2021 Aug; 17(23):3017-3026. PubMed ID: 34044584
[TBL] [Abstract][Full Text] [Related]
34. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Zhao JL; Antonarakis ES; Cheng HH; George DJ; Aggarwal R; Riedel E; Sumiyoshi T; Schonhoft JD; Anderson A; Mao N; Haywood S; Decker B; Curley T; Abida W; Feng FY; Knudsen K; Carver B; Lacouture ME; Wyatt AW; Rathkopf D
Br J Cancer; 2024 Jan; 130(1):53-62. PubMed ID: 37980367
[TBL] [Abstract][Full Text] [Related]
35. Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib.
Tripathi A; Supko JG; Gray KP; Melnick ZJ; Regan MM; Taplin ME; Choudhury AD; Pomerantz MM; Bellmunt J; Yu C; Sun Z; Srinivas S; Kantoff PW; Sweeney CJ; Harshman LC
Clin Cancer Res; 2020 Dec; 26(23):6122-6131. PubMed ID: 32943461
[TBL] [Abstract][Full Text] [Related]
36. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
[TBL] [Abstract][Full Text] [Related]
37. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
[TBL] [Abstract][Full Text] [Related]
38. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
39. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
Serritella AV; Shevrin D; Heath EI; Wade JL; Martinez E; Anderson A; Schonhoft J; Chu YL; Karrison T; Stadler WM; Szmulewitz RZ
Clin Cancer Res; 2022 Apr; 28(8):1549-1559. PubMed ID: 35110415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]